Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity

Off-label rituximab is commonly used for patients with systemic lupus erythematosus (SLE) with extrarenal disease activity. The outcomes and tolerability of rituximab in adult patients with non-renal SLE treated at our hospital from 2013 to 2020 were described. Patients were followed-up until Decemb...

ver descrição completa

Detalhes bibliográficos
Autores: Sans Pola, Carla|||0000-0002-5834-3183, Danés Carreras, Immaculada|||0000-0002-8711-9666, Bosch Gil, Josep Àngel|||0000-0003-2412-2451, Marrero-Álvarez, Patricia|||0000-0002-4875-1431, Cortés, Josefina, Agustí Escasany, M. Antònia|||0000-0003-4594-1122
Tipo de documento: artigo
Data de publicação:2023
País:España
Recursos:Universitat Autònoma de Barcelona
Repositório:Dipòsit Digital de Documents de la UAB
Idioma:inglês
OAI Identifier:oai:ddd.uab.cat:318126
Acesso em linha:https://ddd.uab.cat/record/318126
https://dx.doi.org/urn:doi:10.3389/fmed.2023.1159794
Access Level:Acceso aberto
Palavra-chave:Rituximab
Off-label
Systemic erythematosus lupus
CD20
Effectiveness
Descrição
Resumo:Off-label rituximab is commonly used for patients with systemic lupus erythematosus (SLE) with extrarenal disease activity. The outcomes and tolerability of rituximab in adult patients with non-renal SLE treated at our hospital from 2013 to 2020 were described. Patients were followed-up until December 2021. Data were retrieved from electronic medical records. Response was classified into complete, partial or no response according to the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI 2 K)-based definitions. A total of 44 cycles were administered to 33 patients. Median age was 45 years and 97% were female. Median follow-up was 5.9 years (IQR 3.7-7.2). The most frequent symptoms that motivated rituximab use were thrombocytopenia (30.3%), arthritis (30.3%), neurological manifestations (24.2%) and cutaneous lupus (15.2%). After most treatment cycles a partial remission was achieved. The median SLEDAI-2 K score declined from 9 (IQR 5-13) to 1.5 (IQR 0-4) (p < 0.00001). The median number of flares significantly declined after receiving rituximab. Platelet counts significantly improved in patients with thrombocytopenia and patients with skin disorders or neurological manifestations also had a partial or complete response. Only 50% of patients with a predominant joint involvement had either a complete or a partial response. The median time to relapse after the first cycle was 1.6 years (95% CI, 0.6-3.1). Anti-dsDNA levels decreased significantly after rituximab from a median of 64.3 (IQR 12-373.9) to 32.7 (IQR 10-173), p = 0.00338. The most frequent adverse events were infusion-related reactions (18.2%) and infections (57.6%). All patients needed further treatment to maintain remission or to treat new flares. A partial or complete response was documented after most rituximab cycles in patients with non-renal SLE. Patients with thrombocytopenia, neurolupus, and cutaneous lupus had better response than those with a predominant joint involvement.